Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

摘要: Purpose Pertuzumab, a recombinant humanized monoclonal antibody (2C4), binds to extracellular domain II of the HER-2 receptor and blocks its ability dimerize with other HER receptors. Pertuzumab represents new class targeted therapeutics known as dimerization inhibitors. A clinical study was conducted investigate safety pharmacokinetics pertuzumab perform preliminary assessment inhibition treatment strategy. Patients Methods incurable, locally advanced, recurrent or metastatic solid tumors that had progressed during after standard therapy were recruited dose-escalation (0.5 15 mg/kg) given intravenously every 3 weeks. Results Twenty-one patients received 19 completed at least two cycles. well tolerated. Overall, 365 adverse events reported 122 considered be possibly drug related. Of these, 116 grade 1 2 intensity. The w...